Am­gen, GSK, Re­genxbio and oth­ers urge SCO­TUS to re­view 'dam­ag­ing' de­ci­sion on bio­med­ical patents

The Supreme Court should weigh in on a re­cent Fed­er­al Cir­cuit de­ci­sion that “de­fies his­to­ry and prece­dent” and could up­end the en­tire bio­phar­ma in­no­va­tion ecosys­tem …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER